Research programme: antisense oligonucleotides - EpiGenesis/Aceragen
Alternative Names: RASONs - EpiGenesis/Aceragen; Respirable antisense oligonucleotides - EpiGenesis/AceragenLatest Information Update: 20 Jan 2023
At a glance
- Originator EpiGenesis Pharmaceuticals; Idera Pharmaceuticals
- Developer Aceragen; EpiGenesis Pharmaceuticals
- Class Antisense oligonucleotides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Respiratory tract disorders